HER2传奇：死磕二十年，他们终于改变了乳腺癌治疗的历史(2)

参考资料：

[1] Bazell R. Her-2: The making of herceptin, a revolutionary treatment for breast cancer[M]. Random House, 2011.

[2] EsTEva F J, Hortobagyi G N. Gaining ground on breast cancer[J]. Scientific American, 2008, 298(6): 58-65.

[3] Ullrich A, Coussens L, Hayflick J S, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells[J]. Nature, 1984, 309(5967): 418.

[4] Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor[J]. Nature, 1986, 319(6050): 230.

[5] Fukushige S I, Matsubara K I, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line[J]. Molecular and Cellular Biology, 1986, 6(3): 955-958.

[6] Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. science, 1987, 235(4785): 177-182.

[7] Wieduwilt M J, Moasser M M. The epidermal growth factor receptor family: biology driving targeted therapeutics[J]. Cellular and Molecular Life Sciences, 2008, 65(10): 1566-1584.

[8] Ali R, Wendt M K. The paradoxical functions of EGFR during breast cancer progression[J]. Signal transduction and targeted therapy, 2017, 2: 16042.

[9] Ali R, Wendt M K. The paradoxical functions of EGFR during breast cancer progression[J]. Signal transduction and targeted therapy, 2017, 2: 16042.

[10] Goldenberg D M. Challenges to the therapy of cancer with monoclonal antibodies[J]. Journal of the National Cancer Institute, 1991, 83(2): 78.

[11] Carter P, Presta L E N, Gorman C M, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy[J]. Proceedings of the National Academy of Sciences, 1992, 89(10): 4285-4289.

[12] https://www.gene.com/stories/her2/

[13] https://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can

[14] Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. New England Journal of Medicine, 2001, 344(11): 783-792.

[15] https://www.linkedin.com/pulse/twenty-years-miracle-breast-cancer-drug-sue-desmond-hellmann-md-mph/

[16] https://www.cancer.gov/research/progress/discovery/HER2

[17] Hong S, Gu Y, Gao Z, et al. EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells[J]. Life sciences, 2014, 119(1-2): 28-33.

[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018.

[19] https://clinicaltrials.gov/ct2/show/NCT03588091